GPR52 agonist-1
Modify Date: 2024-04-08 21:47:14
GPR52 agonist-1 structure
|
Common Name | GPR52 agonist-1 | ||
|---|---|---|---|---|
| CAS Number | 1207965-40-9 | Molecular Weight | 453.96 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H21ClFNO2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GPR52 agonist-1GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC50 value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity[1]. |
| Name | GPR52 agonist-1 |
|---|
| Description | GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC50 value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity[1]. |
|---|---|
| Related Catalog | |
| Target |
pEC50: 7.53 (GPR52)[1] |
| In Vivo | GPR52 agonist-1 (compound 7m) (3, 10, and 30 mg/kg; PO; single dosage) attenuates Methamphetamine-induced hyperlocomotion in mice[1]. GPR52 agonist-1 (0.1 mg/kg, IV and 1 mg/kg, PO; single dosage) exhibits good oral pharmacokinetic profile with an Cmax of 108.1 ng/mL, an AUC0-8h of 613.7 ng·h/mL, and an F (bioavailability) of 73% in mouse[1]. Animal Model: Male ICR mice (7-8 weeks; subcutaneously injected with 2 mg/kg Methamphetamine after 60 min administration)[1] Dosage: 3, 10, and 30 mg/kg Administration: PO; single dosage Result: Attenuated Methamphetamine-induced hyperlocomotion dose-dependently. Did not show significant cataleptogenic effects even at a dose of 100 mg/kg and had a low risk of extrapyramidal side effects. |
| References |
| Molecular Formula | C25H21ClFNO2S |
|---|---|
| Molecular Weight | 453.96 |